Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $11.7B | $11.7B | $11.8B |
| Revenue growth | — | 0.2% | 0.9% |
| Gross profit | $2.77B | $3.07B | $3.03B |
| Gross margin | 23.7% | 26.2% | 25.7% |
| Operating income | $1.89B | $2.19B | $1.91B |
| Operating margin | 16.2% | 18.8% | 16.1% |
| Net income | $956M | $1.27B | $1.19B |
| Net margin | 8.2% | 10.9% | 10.0% |
| EPS (diluted) | $1.73 | $2.30 | $2.14 |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | $2.04B | $2.28B | $2.21B |
| Capital expenditures | $630M | $642M | $788M |
| Free cash flow | $1.41B | $1.64B | $1.42B |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cash & equivalents | $1.11B | $1.58B | $1.92B |
| Total assets | — | $23.8B | $24.2B |
| Total liabilities | — | $13.9B | $11.0B |
| Shareholders' equity | $9.20B | $9.91B | $13.3B |
| Retained earnings | — | $0.00 | $902M |
| Shares (wtd avg diluted) | 553M | 553M | 554M |
Every figure is extracted from Amrize Ltd’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.